Crossmark

Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals

Crossref DOI link: https://doi.org/10.1016/j.remnie.2017.09.001

Published Print: 2017-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Vallejo, J.A.

Muros, M.A.
License Information

Text and Data Mining valid from 2017-11-01
More Information

This article is maintained by: Elsevier

Article Title: Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals

Journal Title: Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.remnie.2017.09.001

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.remn.2017.04.005

Content Type: article

Copyright: © 2017 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

Document is current

Any future updates will be listed below